Comparison end-to-end anastomosis with ostomy after secondary surgical cytoreduction for recurrent high-grade serous ovarian cancer: observational single-center study.
Bowel resection
Ovarian cancer
Progression
Secondary cyto-reduction
Survival
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
17
09
2022
accepted:
08
01
2023
medline:
19
5
2023
pubmed:
22
1
2023
entrez:
21
1
2023
Statut:
ppublish
Résumé
We conducted an observational single-center cohort study on patients with recurrent high-grade serous ovarian carcinoma that underwent secondary surgical cytoreduction with extent of partial ileectomy and/or colectomy, followed by adjuvant chemotherapy (Paclitaxel-Carboplatin). All patients performed previously primary debulking surgery without residual disease, followed by three cycles of adjuvant chemotherapy. The aim of this study was to compare survival in patients with ostomy or end-to-end anastomosis that underwent secondary cytoreduction. Furthermore, we investigated the morbidity, the rate, timing and complications of the ostomy or end-to-end anastomosis after secondary cyto-reduction.
Identifiants
pubmed: 36680573
doi: 10.1007/s00404-023-06918-9
pii: 10.1007/s00404-023-06918-9
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
231-237Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424
doi: 10.3322/caac.21492
pubmed: 30207593
Katić K, Matković V, Lešin et al (2019) First-line treatment of ovarian cancer FIGO stages IIIB-IV: focus on therapy with bevacizumab—our experience. Libri Oncol 47(2–3):64–70
Berek JS, Kehoe ST, Kumar L, Friedlander M (2018) Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet 143:59–78
doi: 10.1002/ijgo.12614
Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope RC, Wilson TO et al (2006) Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107:77–85
doi: 10.1097/01.AOG.0000192407.04428.bb
pubmed: 16394043
Chang SJ, Hodeib M, Chang J, Bristow RE (2013) Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol 130:493–498
doi: 10.1016/j.ygyno.2013.05.040
pubmed: 23747291
Tseng JH et al (2016) Diverting ileostomy during primary debulking surgery for ovarian cancer: associated factors and postoperative outcomes. Gynecol Oncol 142(2):217–224
doi: 10.1016/j.ygyno.2016.05.035
pubmed: 27261325
pmcid: 4961543
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Monts FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259
doi: 10.1200/JCO.2002.20.5.1248
pubmed: 11870167
Tozzi R et al (2018) Morbidity and reversal rate of ileostomy after bowel resection during visceral-peritoneal debulking (VPD) in patients with stage IIIC-IV ovarian cancer. Gynecol Oncol 148(1):74–78
doi: 10.1016/j.ygyno.2017.11.017
pubmed: 29169615
Kim M, Suh DH, Park JY et al (2018) Survival impact of low anterior resection in patients with epithelial ovarian cancer grossly confined to the pelvic cavity: a Korean multicenter study. J Gynecol Oncol 29(4):e60
doi: 10.3802/jgo.2018.29.e60
pubmed: 29770630
pmcid: 5981111
Dood RL, Zhao Y, Armbruster SD et al (2018) Defining survivorship trajectories across patients with solid tumors: an evidence-based approach. JAMA Oncol 4:1519–1526
doi: 10.1001/jamaoncol.2018.2761
pubmed: 29860375
Bommert M, Harter P, Heitz F, du Bois A (2018) When should surgery be used for recurrent ovarian carcinoma? Clin Oncol (R Coll Radiol) 30:493–497
doi: 10.1016/j.clon.2018.04.006
pubmed: 29743148
Coleman RL, Spirtos NM, Enserro D et al (2019) Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med 381:1929–1939
doi: 10.1056/NEJMoa1902626
pubmed: 31722153
pmcid: 6941470
Du Bois A, Vergote I, Ferron G et al (2017) Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol 35:5501 (abstract)
doi: 10.1200/JCO.2017.35.15_suppl.5501
Armstrong DK et al (2019) National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: ovarian cancer (version 2.2018). J Natl Compr Canc Netw 17(8):896-909. https://doi.org/10.6004/jnccn.2019.0039
doi: 10.6004/jnccn.2019.0039
pubmed: 31390583
Harter P, Heitz F, du Bois A (2012) Surgery for relapsed ovarian cancer: when should it be offered? Curr Oncol Rep 14(6):539–543
doi: 10.1007/s11912-012-0260-x
pubmed: 22918696
National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in ovarian cancer. Version 1.2017
Petrillo M, Fagotti A, Ferrandina G et al (2013) Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors. Gynecol Oncol 131(1):36–41
doi: 10.1016/j.ygyno.2013.06.020
pubmed: 23791829
Petrillo M, Ferrandina G, Fagotti A et al (2013) Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy. Ann Surg Oncol 20(12):3955–3960
doi: 10.1245/s10434-013-3091-6
pubmed: 23838915
Luo Y, Lee M, Kim HS et al (2016) Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer. Medicine 95:36
doi: 10.1097/MD.0000000000004797
da Costa AA, Valadares CV, Baiocchi G et al (2015) Neoadjuvant chemotherapy followed by interval debulking surgery and the risk of platinum resistance in epithelial ovarian cancer. Ann Surg Oncol 22:971–978
doi: 10.1245/s10434-015-4623-z
Harter P, du Bois A, Hahmann M et al (2006) Surgery in recurrent ovarian cancer: the arbeitsgemeinschaft gynaekologische onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13(12):1702–1710
doi: 10.1245/s10434-006-9058-0
pubmed: 17009163
Harter P, Sehouli J, Reuss A et al (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21(2):289–295
doi: 10.1097/IGC.0b013e31820aaafd
pubmed: 21270612
Richardson DL, Mariani A, Cliby WA (2006) Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol 103(2):667–672
doi: 10.1016/j.ygyno.2006.05.003
pubmed: 16797684
Peiretti M, Bristow RE, Zapardiel I, Gerardi M, Zanagnolo V, Biffi R, Landoni F, Bocciolone L, Aletti GD, Maggioni A (2012) Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecol Oncol 126(2):220–223
doi: 10.1016/j.ygyno.2012.04.030
pubmed: 22555105
Mourton SM, Temple LK, Abu-Rustum NR, Gemignani ML, Sonoda Y, Bochner BH, Barakat RR, Chi DS (2005) Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 99(3):608–614
doi: 10.1016/j.ygyno.2005.07.112
pubmed: 16153697
Fotopoulou C, Planchamp F, Aytulu T, Chiva L, Cina A, Ergönül O et al (2021) European society of gynaecological oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery. Int J Gynecol Cancer 31(9):1199–1206
doi: 10.1136/ijgc-2021-002951
pubmed: 34407962
Sier MF, van Gelder L, Ubbink DT, Bemelman WA, Oostenbroek RJ (2015) Factors affecting timing of closure and non-reversal of temporary ileostomies. Int J Color Dis 30(9):1185–1192
doi: 10.1007/s00384-015-2253-3
Waterland P, Goonetilleke K, Naumann DN, Sutcliff M, Soliman F (2015) Defunctioning ileostomy reversal rates and reasons for delayed reversal: does delay impact on complications of ileostomy reversal? A study of 170 defunctioning ileostomies. J Clin Med Res 7(9):685–689
doi: 10.14740/jocmr2150w
pubmed: 26251682
pmcid: 4522985
Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W et al (2021) DESKTOP III Investigators. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med 385(23):2123–2131
doi: 10.1056/NEJMoa2103294
pubmed: 34874631